Eli Lilly’s Reyvow, squaring off against AbbVie and Biohaven, posts data showing early and lasting migraine relief
With several new acute migraine treatments vying for market share, Eli Lilly is touting new data on Reyvow showing the med can provide patients “pain freedom” in as little as one hour, plus sustained relief for up to two days. In a phase 3 trial called Centurion, patients who took Lilly’s new drug at the 200mg dose were 4.6 times more likely to experience pain… Read More »
